Heimo Lagler - Infectious Diseases

Author Information

Heimo Lagler is affiliated with the Department of Medicine I, Division of Infectious Diseases and Tropical Medicine at the Medical University of Vienna, located in Vienna, Austria. His work is prominently recognized in the field of infectious diseases, focusing on both clinical and research aspects. The affiliation highlights his role in a leading institution for medical research and healthcare.

Research Contributions

Heimo Lagler has made significant contributions to the field of infectious diseases, with research topics ranging from infection control and prevention strategies, such as those implemented during the COVID-19 pandemic, to the treatment of specific infectious diseases like Legionellosis. His studies also extend into broader medical areas, including the evaluation of vaccination uptake among patients with chronic diseases and the investigation of immunotherapeutic approaches targeting cardiovascular conditions. His diverse research portfolio underscores his commitment to advancing understanding and treatment of various health conditions, particularly those related to infectious diseases.

Aliases

Heimo Lagler is also known by the aliases H Lagler and H. Lagler. These variations are commonly used in academic publications and citations.

Publication and Citation Metrics

Metric	Value
Paper Count	87
Citation Count	2015
H-index	25

Publications:

Evaluation of Eosinophilic Cationic Protein as a Marker of Alveolar and Cystic Echinococcosis

DOI: 10.3390/pathogens11020261

Year: 2022

A Longitudinal Seroprevalence Study Evaluating Infection Control and Prevention Strategies at a Large Tertiary Care Center with Low COVID-19 Incidence

DOI: 10.3390/ijerph18084201

Year: 2021

A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9

DOI: 10.1007/s00228-021-03149-2

Year: 2021

Influenza vaccination uptake and factors influencing vaccination decision among patients with chronic kidney or liver disease

DOI: 10.1371/journal.pone.0249785

Year: 2021

Bone turnover markers can predict healing time in medication-related osteonecrosis of the jaw

DOI: 10.1007/s00520-021-06361-z

Year: 2021

Treatment of Legionellosis Including a Single Intravenous Dose of 1.5 g Azithromycin: 18-year Experience at a Tertiary Care Hospital

DOI: 10.1016/j.ijantimicag.2021.106481

Year: 2021

Azithromycin Concentrations During Long-Term Regimen in Patients With MALT Lymphoma

DOI: 10.21203/RS.3.RS-185898/V1

Year: 2021

Comparison of non-invasive Staphylococcus aureus sampling methods on lesional skin in patients with atopic dermatitis

DOI: 10.1007/s10096-021-04365-5

Year: 2021

Evaluation of the safety and efficacy of dihydroartemisinin–piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women: protocol of a multicentre, two-arm, randomised, placebo-controlled, superiority clinical trial (MAMAH project)

DOI: 10.1136/bmjopen-2021-053197

Year: 2021

Azithromycin concentrations during long-term regimen, a pilot study in patients with MALT lymphoma

DOI: 10.1038/s41598-021-97836-w

Year: 2021

When to Use Decongestants?

How Do Antimicrobials Work?

What Skills are Essential for ID Specialists?

How Do Immunodeficiency Disorders Affect Susceptibility to Infections?

What Are the Latest Advances in Immunotherapy?

What Role Do Viruses Play in Infectious Diseases?

What are the Challenges in Controlling Dengue Hemorrhagic Fever?

How Are Muscle Aches Diagnosed?

How to Use Antibiotics Responsibly?

Why is Antibiotic Resistance a Global Health Concern?

Partnered Content Networks

Relevant Topics